The DOI matches its Crossref record; 35 of the 35 references it cites were found in a registry or an index.
Strong induction of PCSK9 gene expression through HNF1α and SREBP2: mechanism for the resistance to LDL-cholesterol lowering effect of statins in dyslipidemic hamsters
Open accessAbstract
We investigated the role of proprotein convertase subtilisin/kexin type 9 (PCSK9) in the resistance of dyslipidemic hamsters to statin-induced LDL-cholesterol (LDL-C) reduction and the molecular mechanism by which statins modulated PCSK9 gene expression in vivo. We utilized the fructose diet-induced dyslipidemic hamsters as an in vivo model and rosuvastatin to examine its effects on liver PCSK9 and LDL receptor (LDLR) expression and serum lipid levels. We showed that rosuvastatin induced PCSK9 mRNA to a greater extent than LDLR mRNA in the hamster liver. The net result was that hepatic LDLR protein level was reduced. This correlated closely with an increase in serum LDL-C with statin treatment. More importantly, we demonstrated that in addition to an increase in sterol response element binding protein 2 (SREBP2) expression, rosuvastatin treatment increased the liver expression of hepatocyte nuclear factor 1 alpha (HNF1alpha), the newly identified key transactivator for PCSK9 gene expression. Our study suggests that the inducing effect of rosuvastatin on HNF1alpha is likely a underlying mechanism accounting for the higher induction of PCSK9 than LDLR because of the utilization of two transactivators (HNF1alpha and SREBP2) in PCSK9 transcription versus one (SREBP2) in LDLR transcription. Thus, the net balance is in favor of PCSK9-induced degradation of LDLR in the hamster liver, abrogating the effect of rosuvastatin on LDL-C lowering.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Kong, W., Wei, J., Abidi, P., Lin, M., Inaba, S., Li, C., Wang, Y., Wang, Z., Si, S., Pan, H., et al. (2004) · Nature Medicine · doi:10.1038/nm1135 · Cited by 1,391
Self-citationSeidah, N. G., Benjannet, S., Wickham, L., Marcinkiewicz, J., Jasmin, S. B., Stifani, S., Basak, A., Prat, A., & Chrétien, M. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0335507100 · Cited by 1,191
Self-citationZhang, D.-W., Lagace, T. A., Garuti, R., Zhao, Z., McDonald, M., Horton, J. D., Cohen, J. C., & Hobbs, H. H. (2007) · Journal of Biological Chemistry · doi:10.1074/jbc.m702027200 · Cited by 788
Molecular biology of PCSK9: its role in LDL metabolism
HORTON, J., COHEN, J., & HOBBS, H. (2007) · Trends in Biochemical Sciences · doi:10.1016/j.tibs.2006.12.008 · Cited by 621
Dubuc, G., Chamberland, A., Wassef, H., Davignon, J., Seidah, N. G., Bernier, L., & Prat, A. (2004) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/01.atv.0000134621.14315.43 · Cited by 570
Self-citationHepatic insulin resistance, metabolic syndrome and cardiovascular disease
Meshkani, R., & Adeli, K. (2009) · Clinical Biochemistry · doi:10.1016/j.clinbiochem.2009.05.018 · Cited by 458
Self-citationShih, D. Q., Bussen, M., Sehayek, E., Ananthanarayanan, M., Shneider, B. L., Suchy, F. J., Shefer, S., Bollileni, J. S., Gonzalez, F. J., Breslow, J. L., et al. (2001) · Nature Genetics · doi:10.1038/86871 · Cited by 422
Li, H., Dong, B., Park, S. W., Lee, H.-S., Chen, W., & Liu, J. (2009) · Journal of Biological Chemistry · doi:10.1074/jbc.m109.052407 · Cited by 348
Self-citationUsui, S., Hara, Y., Hosaki, S., & Okazaki, M. (2002) · Journal of Lipid Research · doi:10.1016/s0022-2275(20)30123-1 · Cited by 333
Jeong, H. J., Lee, H.-S., Kim, K.-S., Kim, Y.-K., Yoon, D., & Park, S. W. (2008) · Journal of Lipid Research · doi:10.1194/jlr.m700443-jlr200 · Cited by 331
Self-citationAtorvastatin increases human serum levels of proprotein convertase subtilisin/kexin type 9
Careskey, H. E., Davis, R. A., Alborn, W. E., Troutt, J. S., Cao, G., & Konrad, R. J. (2008) · Journal of Lipid Research · doi:10.1194/jlr.m700437-jlr200 · Cited by 313
Costet, P., Cariou, B., Lambert, G., Lalanne, F., Lardeux, B., Jarnoux, A.-L., Grefhorst, A., Staels, B., & Krempf, M. (2006) · Journal of Biological Chemistry · doi:10.1074/jbc.m508582200 · Cited by 304
Berberine decreases PCSK9 expression in HepG2 cells
Cameron, J., Ranheim, T., Kulseth, M. A., Leren, T. P., & Berge, K. E. (2008) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2008.02.004 · Cited by 233
Plasma PCSK9 levels are significantly modified by statins and fibrates in humans
Mayne, J., Dewpura, T., Raymond, A., Cousins, M., Chaplin, A., Lahey, K. A., LaHaye, S. A., Mbikay, M., Ooi, T., & Chrétien, M. (2008) · Lipids in Health and Disease · doi:10.1186/1476-511x-7-22 · Cited by 217
Secreted PCSK9 downregulates low density lipoprotein receptor through receptor-mediated endocytosis
Qian, Y.-W., Schmidt, R. J., Zhang, Y., Chu, S., Lin, A., Wang, H., Wang, X., Beyer, T. P., Bensch, W. R., Li, W., et al. (2007) · Journal of Lipid Research · doi:10.1194/jlr.m700071-jlr200 · Cited by 194
Plasma PCSK9 preferentially reduces liver LDL receptors in mice
Grefhorst, A., McNutt, M. C., Lagace, T. A., & Horton, J. D. (2008) · Journal of Lipid Research · doi:10.1194/jlr.m800027-jlr200 · Cited by 183
Lambert, G., Ancellin, N., Charlton, F., Comas, D., Pilot, J., Keech, A., Patel, S., Sullivan, D. R., Cohn, J. S., Rye, K.-A., et al. (2008) · Clinical Chemistry · doi:10.1373/clinchem.2007.099747 · Cited by 166
Antagonism of Secreted PCSK9 Increases Low Density Lipoprotein Receptor Expression in HepG2 Cells
McNutt, M., Kwon, H. J., Chen, C., Chen, J. R., Horton, J. D., & Lagace, T. A. (2009) · Journal of Biological Chemistry · doi:10.1074/jbc.m808802200 · Cited by 159
Abidi, P., Zhou, Y., Jiang, J.-D., & Liu, J. (2005) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/01.atv.0000181761.16341.2b · Cited by 152
Self-citationPeterson, A. S., Fong, L. G., & Young, S. G. (2008) · Journal of Lipid Research · doi:10.1194/jlr.e800008-jlr200 · Cited by 141
Krause, B. R., & Newton, R. S. (1995) · Atherosclerosis · doi:10.1016/0021-9150(95)05576-i · Cited by 113
PCSK9 as a therapeutic target of dyslipidemia
Seidah, N. G. (2009) · Expert Opinion on Therapeutic Targets · doi:10.1517/14728220802600715 · Cited by 110
Self-citationSchmidt, R. J., Beyer, T. P., Bensch, W. R., Qian, Y., Lin, A., Kowala, M. C., Alborn, W. E., Konrad, R. J., & Cao, G. (2008) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2008.04.004 · Cited by 110
Inhibition of PCSK9: A powerful weapon for achieving ideal LDL cholesterol levels
Steinberg, D. H., & Witztum, J. L. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0904560106 · Cited by 106
Li, H., Chen, W., Zhou, Y., Abidi, P., Sharpe, O., Robinson, W. H., Kraemer, F. B., & Liu, J. (2009) · Journal of Lipid Research · doi:10.1194/jlr.m800375-jlr200 · Cited by 85
Self-citationErrata. PCSK9 function and physiology
Peterson, A. S., Fong, L. G., & Young, S. G. (2008) · Journal of Lipid Research · doi:10.1194/jlr.cx00001-jlr200 · Cited by 77
Atorvastatin reverses age‐related reduction in rat hepatic PPARα and HNF‐4
Sanguino, E., Roglans, N., Alegret, M., Sánchez, R. M., Vázquez‐Carrera, M., & Laguna, J. C. (2005) · British Journal of Pharmacology · doi:10.1038/sj.bjp.0706260 · Cited by 60
High doses of atorvastatin and simvastatin induce key enzymes involved in VLDL production
Roglans, N., Verd, J. C., Peris, C., Alegret, M., Vázquez‐Carrera, M., Adzet, T., Díaz, C., Hernández, G., Laguna, J. C., & Sánchez, R. M. (2002) · Lipids · doi:10.1007/s11745-002-0916-0 · Cited by 58
Walsh, K. M., Albassam, M., & Clarke, D. E. (1996) · Toxicologic Pathology · doi:10.1177/019262339602400409 · Cited by 54
Naples, M., Federico, L. M., Xu, E., Nelken, J., & Adeli, K. (2008) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2007.11.003 · Cited by 48
Self-citationIto, B., Zhang, B. L., Cable, E. E., Song, X., Fujitaki, J., MacKenna, D., Wilker, C., Chi, B., Poelje, P. V., Linemeyer, D., et al. (2009) · British Journal of Pharmacology · doi:10.1111/j.1750-3639.2009.00038.x · Cited by 44
Abidi, P., Chen, W., Kraemer, F. B., Li, H., & Liu, J. (2006) · Journal of Lipid Research · doi:10.1194/jlr.m600195-jlr200 · Cited by 43
Self-citationThe guinea pig as a preclinical model for demonstrating the efficacy and safety of statins
Madsen, C. S., Janovitz, E., Zhang, R., Nguyen-Tran, V., Ryan, C. S., Yin, X., Monshizadegan, H., Chang, M., D’Arienzo, C., Scheer, S., et al. (2008) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.107.131615 · Cited by 33
Chong, T. M., Naples, M., Federico, L. M., Taylor, D., Smith, G. J., Cheung, R. C., & Adeli, K. (2005) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2005.05.010 · Cited by 20
Self-citationFurther LDL Cholesterol Lowering Through Targeting PCSK9 for Coronary Artery Disease
Cao, G., Qian, Y., Kowala, M. C., & Konrad, R. J. (2008) · Endocrine Metabolic & Immune Disorders - Drug Targets · doi:10.2174/187153008786848286 · Cited by 19
Cited by
Seidah (2014) · doi:10.1161/circresaha.114.301621 · Cited by 596
Lambert (2012) · doi:10.1194/jlr.r026658 · Cited by 448
PCSK9 and LDLR degradation: regulatory mechanisms in circulation and in cells
Lagace, T. A. (2014) · Current Opinion in Lipidology · doi:10.1097/mol.0000000000000114 · Cited by 372
PCSK9 inhibitors: A new era of lipid lowering therapy
Chaudhary, R., Garg, J., Shah, N., & Sumner, A. (2017) · World Journal of Cardiology · doi:10.4330/wjc.v9.i2.76 · Cited by 299
PCSK9: From Basic Science Discoveries to Clinical Trials
Shapiro, M. D., Tavori, H., & Fazio, S. (2018) · Circulation Research · doi:10.1161/circresaha.118.311227 · Cited by 285
Metadata
- Authors
- Dong, B., Wu, M., Li, H., Kraemer, F. B., Adeli, K., Seidah, N. G., Park, S. W., & Liu, J.
- Venue
- Journal of Lipid Research
- Publisher
- Elsevier BV
- Published
- 2010-06
- Volume
- 51
- Issue
- 6
- Pages
- 1486-1495
- ISSN
- 0022-2275 (ISSN-L)
- OpenAlex
- W2127729207
- Cited by
- 266
- References
- 35
- FWCI
- 13.35
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.